Wilson Disease - Clues in Acute Liver Failure

Key Points

• Think of Wilson disease in young patients with unexplained acute liver failure and hemolytic anemia.
• Low alkaline phosphatase relative to a very high bilirubin is a classic clue.
• Ceruloplasmin can be normal in acute liver failure and cannot exclude Wilson disease.
• Do not delay transfer for liver transplantation while waiting for complete copper testing.
• Chelation is effective for chronic Wilson disease but does not reliably rescue Wilson-associated acute liver failure.
• Plasma exchange can be used as a bridge to transplantation in severe Wilsonian crisis.
• Screen siblings and other at-risk relatives after diagnosis.

Algorithm

1. Recognize acute liver failure with hemolysis or a suggestive biochemical pattern.
2. Send CBC, hemolysis studies, liver tests, INR, renal function, ceruloplasmin, serum and urinary copper testing as feasible.
3. Contact a liver transplant center immediately.
4. Provide standard ALF neurocritical, glucose, renal, and infection management.
5. Use plasma exchange or other extracorporeal support as a bridge in specialist centers when indicated.
6. Do not allow chelation trials or biopsy to delay transplantation.
7. Confirm diagnosis with specialist testing and initiate family screening after stabilization.

Clinical Synopsis & Reasoning

Wilson disease is an autosomal recessive ATP7B disorder that impairs biliary copper excretion, causing copper accumulation in liver, brain, cornea, kidneys, and other tissues. Acute liver failure from Wilson disease is a special emergency because the diagnostic pattern differs from chronic neurologic or hepatic Wilson disease and spontaneous survival without liver transplantation is extremely poor. Patients are often adolescents or young adults but can present outside the stereotyped age range.

Clues include acute liver failure with Coombs-negative intravascular hemolysis, high bilirubin with a relatively low alkaline phosphatase, modest aminotransferase elevation compared with the degree of failure, renal dysfunction, and a prior history of neuropsychiatric symptoms or unexplained liver abnormalities. The alkaline phosphatase-to-total bilirubin ratio can be strikingly low, and AST may exceed ALT. Ceruloplasmin can be low but may also be normal in acute inflammation or ALF, so it cannot rule the disease in or out by itself.

Send serum copper, ceruloplasmin, 24-hour urinary copper when feasible, hemolysis studies, and ophthalmologic examination for Kayser-Fleischer rings, but do not delay transplant-center transfer for perfect confirmation. Liver biopsy may be unsafe in coagulopathic ALF and is not required before urgent transplant evaluation when the clinical syndrome is convincing.

Treatment Strategy & Disposition

Manage as acute liver failure in an ICU with immediate transplant-center involvement. Protect airway and brain, treat hypoglycemia, avoid hypotension and infection, and use renal support when necessary. Wilson-associated ALF is a transplantation emergency. The 2026 AASLD educational review emphasizes that chelation therapy used for chronic Wilson disease has not been shown to reverse the acute fulminant crisis and should not delay transplantation.

Therapeutic plasma exchange can rapidly remove circulating copper and hemolysis-related products and is often used as a bridge to transplant in severe Wilsonian crisis. Other extracorporeal liver-support strategies may be considered in specialist centers. Treat severe anemia and renal complications supportively. NAC may be used as part of general ALF support but does not correct the underlying copper crisis.

After transplantation, Wilson disease is effectively corrected at the hepatic metabolic level because the donor liver restores functional copper transport. Family screening is important because siblings have substantial genetic risk. Patients diagnosed before ALF are treated with copper chelation or zinc according to phenotype and specialist guidance, but those chronic regimens should not be confused with definitive rescue of Wilson-associated ALF.

Epidemiology / Risk Factors

• Wilson disease is rare but must be recognized because it is treatable before fulminant failure and transplantable after ALF.
• Presentation ranges from asymptomatic transaminase elevation to cirrhosis, movement disorder, psychiatric symptoms, or ALF.
• Siblings of an affected patient have a high enough risk to warrant formal screening.
• Delayed diagnosis is common when psychiatric or neurologic symptoms precede liver findings.

Investigations

Suggestive Lab Pattern

Pharmacology

Prognosis / Complications

• Wilson-associated ALF has extremely poor spontaneous survival without liver transplantation.
• Emergency transplantation provides excellent long-term survival in appropriate candidates.
• Plasma exchange can stabilize hemolysis and copper burden but is generally a bridge rather than definitive therapy.
• Patients treated before fulminant failure can often achieve long-term control with lifelong medical therapy.

Patient Education / Counseling

• Explain that the acute crisis results from inherited copper accumulation and is not caused by dietary behavior alone.
• Discuss urgent transplantation clearly because waiting for medical chelation response can be dangerous in ALF.
• After stabilization, first-degree relatives should receive genetic and biochemical screening.
• Long-term survivors without transplant require lifelong adherence to copper-directed therapy and monitoring.

Notes

Wilson disease is one of the few acute liver-failure etiologies where a pattern of routine laboratory tests can be more immediately useful than a single specialized test. Young age, hemolysis, low alkaline phosphatase relative to bilirubin, and severe synthetic failure should trigger the diagnosis before copper studies return.

Current AASLD educational guidance is explicit that transplant should not be delayed for chelation in Wilsonian acute liver failure. The medical therapies familiar from chronic Wilson disease operate too slowly for this crisis.

References

1. AASLD 2022 Practice Guidance: Diagnosis and Treatment of Wilson Disease — Link
2. AASLD 2026 Hepatology Practice Board Questions: Wilson Disease Acute Liver Failure — Link